Zinacef: Uses, Dosage & Side Effects
An injectable second-generation cephalosporin antibiotic used to treat serious bacterial infections and for surgical prophylaxis in hospital settings
Zinacef is the brand name for cefuroxime sodium, a second-generation cephalosporin antibiotic administered by injection or intravenous infusion. It is used to treat a variety of serious bacterial infections of the lungs, urinary tract, skin, soft tissues, and abdomen, as well as for the prevention of infections during surgical procedures. Cefuroxime works by killing bacteria through disruption of their cell wall synthesis and is notable for its stability against many common bacterial beta-lactamase enzymes. Zinacef is a prescription-only hospital medication listed on the WHO Model List of Essential Medicines.
Quick Facts: Zinacef
Key Takeaways
- Zinacef (cefuroxime) is a second-generation cephalosporin antibiotic given by injection or infusion, used to treat serious bacterial infections of the chest, urinary tract, skin, soft tissues, and abdomen in hospital settings.
- Do not receive Zinacef if you have a known allergy to cephalosporins or have had a severe allergic reaction (anaphylaxis) to any penicillin or other beta-lactam antibiotic; serious and potentially fatal reactions can occur.
- Zinacef is widely used for surgical prophylaxis, helping prevent post-operative infections during a range of surgical procedures including orthopedic, abdominal, and cardiac surgery.
- Common side effects include injection site reactions, transient changes in liver enzymes and blood counts; uncommon effects include diarrhea, nausea, and skin rash. Report severe diarrhea or skin reactions immediately.
- Cefuroxime is generally considered safe during pregnancy and breastfeeding when clinically indicated, and pediatric dosing is based on body weight with well-established protocols for neonates, infants, and children.
What Is Zinacef and What Is It Used For?
Zinacef contains the active substance cefuroxime, administered as its sodium salt (cefuroxime sodium). It belongs to the cephalosporin class of antibiotics, which are part of the broader beta-lactam antibiotic family. Specifically, cefuroxime is classified as a second-generation cephalosporin, meaning it offers improved activity against certain Gram-negative bacteria compared to first-generation cephalosporins, while retaining good coverage of most Gram-positive organisms. Cefuroxime has been in clinical use since the late 1970s and remains an important drug in hospital-based infectious disease management worldwide.
The mechanism of action of cefuroxime is bactericidal: it works by binding to penicillin-binding proteins (PBPs) on the bacterial cell membrane, which are enzymes essential for the final transpeptidation step in peptidoglycan synthesis. Peptidoglycan is the structural polymer that gives the bacterial cell wall its rigidity and protects the cell from osmotic lysis. When cefuroxime inhibits PBPs, the cell wall becomes defective, and the bacterium swells and ruptures due to osmotic pressure, resulting in cell death. Because mammalian cells lack peptidoglycan, cefuroxime is selectively toxic to bacteria.
A key advantage of cefuroxime over many first-generation cephalosporins and some penicillins is its enhanced stability against certain beta-lactamase enzymes produced by bacteria. Beta-lactamases are the most common mechanism of bacterial resistance to beta-lactam antibiotics, and cefuroxime's molecular structure provides relative resistance to hydrolysis by these enzymes, particularly TEM-1 and SHV-1 beta-lactamases commonly produced by Escherichia coli and Klebsiella pneumoniae. However, cefuroxime is not active against extended-spectrum beta-lactamase (ESBL)-producing organisms or methicillin-resistant Staphylococcus aureus (MRSA).
Cefuroxime has a well-characterized spectrum of antibacterial activity. It is effective against a range of Gram-positive organisms including Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pneumoniae, and Streptococcus pyogenes. Its Gram-negative coverage includes Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Klebsiella species, and Proteus mirabilis. It also has some activity against certain anaerobes, although it is not reliably active against Bacteroides fragilis.
Zinacef is indicated for the treatment of the following infections when caused by susceptible organisms:
- Lower respiratory tract infections: Community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, and other lower respiratory tract infections caused by susceptible bacteria.
- Urinary tract infections: Including pyelonephritis (upper urinary tract infection) and complicated and uncomplicated lower urinary tract infections.
- Skin and soft tissue infections: Including cellulitis, wound infections, and erysipelas caused by susceptible organisms.
- Intra-abdominal infections: Including peritonitis and biliary tract infections, often in combination with an agent active against anaerobic bacteria such as metronidazole.
- Bone and joint infections: Including osteomyelitis and septic arthritis.
- Meningitis: Cefuroxime achieves adequate cerebrospinal fluid (CSF) concentrations when the meninges are inflamed, although third-generation cephalosporins are generally preferred for bacterial meningitis.
- Gonorrhea: Uncomplicated gonococcal urethritis and cervicitis.
- Surgical prophylaxis: Prevention of post-operative infections during clean and clean-contaminated surgical procedures, including orthopedic, abdominal, pelvic, cardiac, and thoracic surgery.
Your doctor may test the bacteria causing your infection to confirm that they are susceptible to cefuroxime before or during treatment. This practice, known as antimicrobial susceptibility testing, helps ensure that the antibiotic will be effective and supports responsible antibiotic stewardship. Cefuroxime is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its clinical importance and widespread availability.
Zinacef only works against bacterial infections. It will not treat viral infections such as the common cold, influenza, or COVID-19. Using antibiotics when they are not needed contributes to antibiotic resistance, which the WHO recognizes as one of the greatest threats to global health. Only use Zinacef when prescribed by a healthcare professional for a confirmed or strongly suspected bacterial infection.
What Should You Know Before Receiving Zinacef?
Contraindications
There are specific situations where Zinacef must not be used. Understanding these absolute contraindications is essential for safe treatment.
- Cephalosporin allergy: Do not receive Zinacef if you have a known allergy (hypersensitivity) to cefuroxime, any other cephalosporin antibiotic, or any of the excipients in the product. Patients with a history of severe allergic reactions (anaphylaxis, angioedema, or severe skin reactions) to any cephalosporin must avoid all cephalosporin antibiotics.
- Severe beta-lactam hypersensitivity: If you have ever experienced a severe immediate hypersensitivity reaction (such as anaphylaxis) to any other type of beta-lactam antibiotic, including penicillins, monobactams, or carbapenems, you must not receive Zinacef.
- History of severe skin reactions: Do not use cefuroxime if you have previously experienced severe skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS) following treatment with cefuroxime or another cephalosporin.
Warnings and Precautions
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving cephalosporin antibiotics. These reactions are more likely in individuals with a history of hypersensitivity to beta-lactam antibiotics. If you have a history of mild penicillin allergy, cefuroxime may be used with caution, but if you have ever had a severe reaction (anaphylaxis) to any penicillin, you must not receive Zinacef. If an allergic reaction occurs during treatment, the infusion or injection must be stopped immediately and appropriate emergency treatment initiated.
You should inform your healthcare provider before receiving Zinacef if any of the following conditions apply to you:
- Mild penicillin allergy: There is a low cross-reactivity rate (approximately 1–2%) between penicillins and cephalosporins. If you have a mild, non-severe history of penicillin allergy, your doctor may consider prescribing cefuroxime with appropriate monitoring, but you must be observed carefully for any signs of an allergic reaction.
- Impaired kidney function: Cefuroxime is eliminated primarily by the kidneys. In patients with significant renal impairment, the dose should be reduced or the dosing interval extended to prevent accumulation and potential toxicity. Your doctor will adjust the dose based on your kidney function (creatinine clearance).
- History of gastrointestinal disease: Broad-spectrum antibiotics including cefuroxime can cause Clostridioides difficile-associated diarrhea (CDAD), which ranges from mild diarrhea to potentially fatal pseudomembranous colitis. This complication can occur during or after treatment. Contact your doctor immediately if you develop severe, persistent, or bloody diarrhea.
- Prolonged treatment: If cefuroxime is used for an extended period, overgrowth of non-susceptible organisms (including fungi such as Candida) may occur. Periodic monitoring of organ function, including renal and hepatic parameters, is advisable during prolonged courses.
- Concurrent nephrotoxic drugs: Cefuroxime should be used with caution in patients who are simultaneously receiving other medications known to be toxic to the kidneys, such as aminoglycoside antibiotics or potent diuretics like furosemide, as the combination may increase the risk of renal impairment.
Cefuroxime can interfere with certain laboratory tests. It may cause false-positive results in urine glucose tests that use the copper-reduction method (such as Benedict's test, Fehling's solution, or Clinitest). Glucose oxidase-based methods are not affected and should be used instead. Cefuroxime can also cause a false-positive direct Coombs test, which is relevant for patients being cross-matched for blood transfusion or for the monitoring of certain hematological conditions.
Drug Interactions
Several medications can interact with Zinacef. Inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
| Interacting Drug | Type | Effect | Clinical Advice |
|---|---|---|---|
| Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) | Major | Increased risk of nephrotoxicity (kidney damage) when used together | Monitor kidney function closely; do not mix in the same syringe or infusion bag |
| Probenecid | Moderate | Reduces renal tubular secretion of cefuroxime, leading to higher and more prolonged blood levels | May require dose adjustment; inform your doctor if you are taking probenecid |
| Loop diuretics (furosemide) | Moderate | May increase the risk of nephrotoxicity when co-administered with cephalosporins | Monitor renal function; stay adequately hydrated |
| Oral anticoagulants (warfarin) | Moderate | Cephalosporins may rarely enhance the anticoagulant effect, increasing bleeding risk | Monitor INR more frequently during and after cefuroxime therapy |
| Oral contraceptives | Minor | May potentially reduce the effectiveness of hormonal contraceptives | Use additional barrier contraception (e.g., condoms) during treatment and for 7 days afterward |
Pregnancy and Breastfeeding
Cefuroxime crosses the placenta and is present in the fetal circulation. Animal reproductive studies have not demonstrated evidence of embryotoxicity or teratogenicity. There are limited controlled studies of cefuroxime in pregnant women, but extensive clinical experience supports the view that cephalosporins as a class are generally considered safe during pregnancy. Cefuroxime is categorized as FDA Pregnancy Category B, meaning that animal studies have shown no risk but adequate human data are limited.
Despite this favorable safety profile, Zinacef should only be used during pregnancy when the expected clinical benefit outweighs the potential risk to the fetus. Your doctor will carefully weigh the need to treat your infection against any theoretical risks. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, inform your healthcare provider before receiving Zinacef.
Cefuroxime is excreted in breast milk in small quantities. At therapeutic doses, the amount transferred to the nursing infant is generally considered too small to be clinically significant. However, there is a theoretical risk that the infant's gut flora could be altered, potentially leading to diarrhea or candidiasis (thrush). If you are breastfeeding, your doctor will assess the benefit of treatment to you against any potential effects on your baby.
Driving and Operating Machinery
Cefuroxime has no known direct effect on the ability to drive or operate machinery. However, as with any medication, adverse effects can occasionally occur. If you experience dizziness, drowsiness, or any other symptoms that could impair your concentration or reaction time during or after treatment with Zinacef, do not drive or operate machinery until you feel well. Discuss any concerns with your healthcare provider.
Sodium Content
Zinacef contains sodium as part of its formulation (cefuroxime sodium). This is important for patients on a sodium-restricted diet. The 250 mg vial contains less than 1 mmol (23 mg) of sodium per vial and is essentially sodium-free. The 750 mg vial contains approximately 42 mg of sodium per vial (equivalent to 2.1% of the WHO-recommended maximum daily intake of 2 g sodium for an adult). The 1.5 g vial contains approximately 83 mg of sodium per vial (equivalent to 4.15% of the recommended maximum daily intake). Inform your doctor if you are on a sodium-controlled diet, especially if you require high or frequent doses.
What Is the Correct Dosage of Zinacef?
Zinacef is supplied as a powder that must be reconstituted (dissolved) with sterile water for injections or a compatible intravenous solution before administration. It is always prepared and administered by a qualified healthcare professional in a hospital or clinical setting. You will never need to prepare or inject this medication yourself. The appropriate dose depends on the severity and type of infection, your body weight and age, and your kidney function.
Adults and Adolescents
Standard Adult Dosing
The usual dose for adults and adolescents is 750 mg to 1.5 g given by intravenous or intramuscular injection two, three, or four times daily, depending on the severity of the infection. The maximum recommended daily dose is 6 g (divided into multiple administrations).
| Indication | Dose | Frequency | Route |
|---|---|---|---|
| Mild to moderate infections | 750 mg | Every 8 hours (three times daily) | IV or IM |
| Severe or life-threatening infections | 1.5 g | Every 6–8 hours | IV |
| Surgical prophylaxis | 1.5 g | Single dose at induction of anesthesia; may be followed by 750 mg every 8 hours for up to 24–48 hours | IV |
| Uncomplicated urinary tract infection | 750 mg | Every 8 hours | IV or IM |
| Uncomplicated gonorrhea | 1.5 g | Single dose (may be given as two 750 mg injections at different sites) | IM |
Children and Infants
Pediatric doses of Zinacef are calculated based on the child's body weight. The usual dose range is 30 to 100 mg per kilogram per day, divided into three or four equal doses. The exact dose within this range depends on the type and severity of the infection.
Neonates (0–3 weeks)
For neonates from birth to 3 weeks of age, the recommended dose is 30 to 100 mg/kg/day divided into two or three equal doses. Neonates have immature renal function, and clearance of cefuroxime is reduced in this age group, necessitating careful dosing and monitoring.
Infants (>3 weeks) and Children
For infants older than 3 weeks and children, the recommended dose is 30 to 100 mg/kg/day divided into three or four equal doses. For most infections, a dose of 60 mg/kg/day is appropriate. For severe infections, particularly bone and joint infections or meningitis, doses up to 100 mg/kg/day may be used (not exceeding the maximum adult dose of 6 g/day).
Patients with Kidney Problems
Because cefuroxime is eliminated primarily through the kidneys, dose adjustment is necessary in patients with significantly impaired renal function. Your doctor will calculate the appropriate dose based on your creatinine clearance (a measure of kidney function). Generally, no adjustment is needed if creatinine clearance is above 20 ml/min. For patients with more severe renal impairment or those receiving dialysis, both the dose and frequency may need to be reduced. If you have known kidney problems, ensure your healthcare team is aware so that appropriate adjustments can be made.
How Zinacef Is Administered
Zinacef can be given by three routes, all of which require preparation by a healthcare professional:
- Intravenous (IV) bolus injection: The reconstituted solution is injected slowly into a vein, typically over 3 to 5 minutes. This route provides the fastest onset of action.
- Intravenous (IV) infusion (drip): The reconstituted solution is further diluted in a compatible intravenous fluid (such as 0.9% sodium chloride or 5% glucose) and infused into a vein over 15 to 60 minutes. This method is often used for larger doses or when a slower rate of administration is preferred.
- Intramuscular (IM) injection: The reconstituted suspension is injected deep into a large muscle, such as the gluteus maximus (buttock) or the lateral aspect of the thigh. IM injection may be used when IV access is not available or for less severe infections.
Zinacef powder must be dissolved before use. The color of the reconstituted solution may range from pale yellow to amber, depending on the concentration and diluent used. This variation in color does not indicate reduced potency or safety. Do not use the solution if it contains visible particulate matter or is severely discolored. Reconstituted solutions should be used promptly or stored according to specific stability guidelines (up to 5 hours at room temperature or up to 72 hours refrigerated for injection solutions).
How Does Zinacef Interact with Other Drugs?
Drug interactions with Zinacef are clinically significant because they can alter the efficacy of treatment or increase the risk of adverse effects. The most important interactions involve medications that affect kidney function, as cefuroxime is primarily eliminated through renal excretion. Your healthcare team will review all your current medications before starting Zinacef treatment.
Aminoglycoside Antibiotics
The combination of cefuroxime with aminoglycoside antibiotics (such as gentamicin, tobramycin, or amikacin) is common in clinical practice, particularly for severe infections where synergistic antibacterial activity is desired. However, both drug classes can be nephrotoxic (harmful to the kidneys), and concomitant use increases the risk of renal impairment. When this combination is necessary, kidney function must be monitored frequently through blood tests measuring serum creatinine and urea. Additionally, cefuroxime and aminoglycosides must never be mixed in the same syringe or intravenous bag, as they are physically incompatible and may undergo degradation.
Probenecid
Probenecid is a uricosuric agent (used to treat gout) that inhibits the renal tubular secretion of many drugs, including cefuroxime. When probenecid is co-administered with Zinacef, the renal clearance of cefuroxime is significantly reduced, leading to higher and more prolonged serum concentrations. While this interaction has occasionally been used therapeutically (to boost antibiotic levels), it requires awareness and potentially dose adjustment to avoid accumulation-related toxicity. Inform your healthcare provider if you are taking probenecid.
Loop Diuretics
High doses of loop diuretics such as furosemide, when given concurrently with cephalosporins, may increase the risk of nephrotoxicity. The mechanism involves additive effects on renal tubular function. Patients receiving both Zinacef and potent diuretics should have their kidney function monitored regularly, and adequate hydration should be maintained throughout the treatment course.
Oral Anticoagulants
As with other cephalosporins, cefuroxime may rarely enhance the effect of vitamin K antagonists such as warfarin, leading to an increased risk of bleeding. This effect is thought to relate to suppression of vitamin K-producing gut flora. Patients receiving both Zinacef and oral anticoagulants should have their International Normalized Ratio (INR) monitored more frequently during and shortly after cefuroxime therapy, with dose adjustments of the anticoagulant as necessary.
Oral Contraceptives
Broad-spectrum antibiotics, including cephalosporins, may theoretically reduce the efficacy of combined oral contraceptive pills by disrupting the enterohepatic recirculation of estrogens. While the clinical significance of this interaction is debated in the medical literature and large studies have not confirmed a significant effect, some prescribing guidelines recommend using additional barrier contraception (such as condoms) during antibiotic treatment and for 7 days after completing the course as a precautionary measure.
What Are the Side Effects of Zinacef?
Like all antibiotics, Zinacef can cause side effects, although not everyone who receives the medication will experience them. Most side effects are mild and transient, resolving after the course of treatment is completed. However, some effects can be serious and require immediate medical attention. The side effects listed below are categorized by frequency, based on clinical trial data and post-marketing surveillance reports.
Conditions to Watch For
A small number of patients receiving Zinacef may develop an allergic reaction or a severe skin reaction. Symptoms to be aware of include:
- Severe allergic reaction (anaphylaxis): Signs include raised, itchy rash (hives), swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, dizziness, and loss of consciousness. This is a medical emergency requiring immediate treatment with epinephrine (adrenaline).
- Severe skin reactions: Rashes that may blister and resemble small targets (dark center with a lighter ring); widespread rash with blistering and peeling of the skin (Stevens-Johnson syndrome or toxic epidermal necrolysis); or widespread rash accompanied by high fever and enlarged lymph nodes (DRESS syndrome). Seek medical attention immediately if you notice any of these symptoms.
- Chest pain during an allergic reaction: In rare cases, allergic reactions may trigger symptoms suggestive of an allergically-mediated cardiac event (Kounis syndrome).
- Severe diarrhea (pseudomembranous colitis): Medicines like Zinacef can cause inflammation of the large intestine, resulting in severe diarrhea (usually with blood and mucus), abdominal pain, and fever. Contact your doctor immediately if this occurs during or after treatment.
Side Effects by Frequency
Common
May affect up to 1 in 10 people
- Pain, swelling, or redness at the injection site
- Thrombophlebitis (inflammation of the vein used for IV injection)
- Transient increase in liver enzymes (detected on blood tests)
- Changes in white blood cell count (neutropenia or eosinophilia)
- Low red blood cell levels (anemia, detected on blood tests)
Uncommon
May affect up to 1 in 100 people
- Skin rash
- Urticaria (hives; itchy, raised bumps on the skin)
- Diarrhea
- Nausea
- Abdominal pain or discomfort
- Decreased white blood cell count (leukopenia)
- Increased bilirubin levels (detected on blood tests)
- Positive Coombs test (a blood test result; usually no clinical significance)
Rare / Frequency Not Known
Reported in a small number of people; exact frequency not established
- Severe allergic reactions (anaphylaxis)
- Drug fever (elevated temperature caused by the medication)
- Fungal superinfection (e.g., oral or vaginal candidiasis/thrush)
- Clostridioides difficile-associated colitis (pseudomembranous colitis)
- Interstitial nephritis (inflammation of the kidneys)
- Vasculitis (inflammation of blood vessels)
- Hemolytic anemia (premature destruction of red blood cells)
- Erythema multiforme (target-like skin lesions)
- Stevens-Johnson syndrome or toxic epidermal necrolysis
- DRESS syndrome
- Decreased platelet count (thrombocytopenia)
- Elevated blood urea nitrogen and serum creatinine
If you experience any side effects, including any not listed on this page, tell your healthcare team. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information about the safety of this medicine.
How Should Zinacef Be Stored?
Zinacef is a hospital medication, and its storage and preparation are managed by pharmacy and nursing staff. However, understanding the storage requirements provides useful context about the product's stability and handling.
- Unopened vials: Store at or below 25°C (77°F). Keep the vials in the outer carton to protect from light. Do not use the product after the expiry date printed on the packaging.
- Reconstituted solution for injection: Stable for up to 5 hours when stored below 25°C, or up to 72 hours when refrigerated at 2–8°C.
- Reconstituted solution for infusion: Stable for up to 3 hours when stored below 25°C, or up to 72 hours when refrigerated at 2–8°C.
- Microbiological safety: From a microbiological standpoint, the reconstituted product should ideally be used immediately. If not used immediately, the healthcare professional is responsible for ensuring appropriate storage conditions and timing, which should normally not exceed 24 hours at 2–8°C unless reconstitution was performed under validated aseptic conditions.
Keep all medicines out of the sight and reach of children. Do not dispose of unused medications via household waste or wastewater. Your healthcare facility will follow local guidelines for the safe disposal of unused pharmaceutical products in an environmentally responsible manner.
What Does Zinacef Contain?
Zinacef has a remarkably simple formulation. The active substance is cefuroxime, present in the form of cefuroxime sodium. Each vial contains a specified amount of cefuroxime:
- 250 mg vial: Contains 250 mg of cefuroxime (as cefuroxime sodium)
- 750 mg vial: Contains 750 mg of cefuroxime (as cefuroxime sodium)
- 1.5 g vial: Contains 1.5 g (1,500 mg) of cefuroxime (as cefuroxime sodium)
There are no other ingredients (excipients) in Zinacef. The sodium component comes from the cefuroxime sodium salt itself. The product is supplied as a powder in colorless glass vials sealed with bromobutyl rubber stoppers and aluminum crimps with a plastic flip-off cap. Available pack sizes include boxes of 5 vials in each strength.
The marketing authorization holder is Sandoz A/S, and the product is manufactured by ACS Dobfar S.p.A. in Verona, Italy. Zinacef is approved and marketed in numerous countries worldwide, reflecting its established role in clinical medicine.
Frequently Asked Questions About Zinacef
Zinacef is the injectable form of cefuroxime, given by IV or IM injection in hospital settings for more serious infections. Oral cefuroxime (marketed as cefuroxime axetil, under brand names such as Zinnat or Ceftin) is a prodrug taken as tablets or oral suspension for less severe infections on an outpatient basis. The injectable form achieves higher blood levels more rapidly, making it more suitable for severe, systemic, or life-threatening infections. Doctors sometimes start treatment with injectable Zinacef and then switch to oral cefuroxime once the patient improves, a strategy known as IV-to-oral switch therapy.
If you have a mild, non-severe history of penicillin allergy, your doctor may decide that cefuroxime can be used with appropriate monitoring, as the cross-reactivity rate between penicillins and cephalosporins is low (approximately 1–2%). However, if you have a history of severe allergic reaction (anaphylaxis, severe skin reactions, or angioedema) to any penicillin or other beta-lactam antibiotic, Zinacef must not be used. Always disclose your full allergy history to your healthcare team before receiving any antibiotic.
The duration of Zinacef treatment depends on the type and severity of the infection. For most infections, treatment typically lasts 5 to 10 days. For surgical prophylaxis, a single dose may be given at the time of anesthesia induction, possibly followed by additional doses for up to 24–48 hours. For serious infections such as osteomyelitis or meningitis, longer courses may be necessary. Your doctor will determine the appropriate duration based on your clinical response and the nature of your infection. It is important to complete the full prescribed course even if you feel better, to prevent treatment failure and antibiotic resistance.
Yes, cefuroxime can cause false-positive results in urine glucose tests that use the copper-reduction method (such as Clinitest, Benedict's solution, or Fehling's solution). This means the test may incorrectly indicate high sugar levels in the urine. If you need urine glucose monitoring, glucose oxidase-based test methods (such as Clinistix or Diastix) should be used instead, as they are not affected. Cefuroxime can also cause a false-positive direct Coombs test, which may be relevant for blood transfusion cross-matching. Always inform laboratory staff that you are receiving cefuroxime.
Zinacef is compatible with several common intravenous solutions, including 0.9% sodium chloride, 5% glucose, Ringer's lactate solution, and Hartmann's solution. It is also compatible with metronidazole injection (500 mg/100 ml) and heparin (10 and 50 units/ml in 0.9% sodium chloride). However, Zinacef must never be mixed with aminoglycoside antibiotics (such as gentamicin) in the same syringe or infusion bag, as they are physically and chemically incompatible. If both drugs are needed, they should be administered through separate IV lines or with adequate flushing between infusions. Always follow hospital pharmacy guidelines for drug compatibility.
Zinacef can be used in neonates, including premature infants, at reduced doses calculated by body weight (30–100 mg/kg/day in two or three divided doses). Neonates have immature kidney function, which means cefuroxime is cleared more slowly, requiring careful dose adjustment and monitoring. Your child's pediatrician or neonatologist will determine the appropriate dose and monitor for any adverse effects. Cefuroxime has a well-established safety profile in pediatric medicine and has been used in neonatal care for decades.
References
All medical information on this page is based on international guidelines, official prescribing information, and peer-reviewed medical literature. The following sources were used:
- 1 World Health Organization (WHO). Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- 2 European Medicines Agency (EMA). Cefuroxime Sodium – Summary of Product Characteristics. EMA; 2024.
- 3 U.S. Food and Drug Administration (FDA). Zinacef (Cefuroxime) – Prescribing Information. FDA; 2023.
- 4 British National Formulary (BNF). Cefuroxime Monograph. NICE Evidence Services; 2024.
- 5 Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. American Journal of Health-System Pharmacy. 2013;70(3):195–283.
- 6 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases. 1998;26(1):1–10.
- 7 Patel IH, Kaplan SA. Pharmacokinetic profile of cefuroxime in man. American Journal of Medicine. 1984;77(4C):7–16.
- 8 World Health Organization. AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use. Geneva: WHO; 2023.
About Our Medical Editorial Team
This article has been researched, written, and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with expertise in clinical pharmacology, infectious disease, and antimicrobial therapy. Our content follows the GRADE evidence framework and adheres to international medical guidelines from the WHO, EMA, FDA, and BNF.
Written by qualified medical professionals with expertise in pharmacology and infectious disease medicine. All claims are supported by peer-reviewed evidence and official prescribing information.
Independently reviewed by the iMedic Medical Review Board to ensure accuracy, balance, and adherence to current clinical guidelines. Last reviewed: May 10, 2026.
We use Evidence Level 1A as our standard: systematic reviews and meta-analyses of randomized controlled trials. All sources are disclosed in our references section.
iMedic receives no commercial funding from pharmaceutical companies. Our editorial content is entirely independent, ensuring unbiased medical information for all readers.